Anixa Biosciences, Inc.
NASDAQ:ANIXBiotechnology
+$0.10 today
- Market cap
- $94.21M
- Beta
- 0.60
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$0.30
Volume 0.29M
Average 0.12M
ANIX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Anixa Biosciences, Inc.NASDAQ: ANIX
Cash & Equivalents · Q2 FY2026 · quarter ended Apr 2026
Cash & equivalents falls 22.7% from a year ago
Cash & equivalents stood at $1.48M at the end of Q2 FY2026, down 22.7% from a year earlier and down 4.5% from the prior quarter. Over 3 fiscal years it compounded at -53.5% a year.
Context
- Cash & equivalents amounted to 9.9% of total assets at the end of Q2 FY2026, down 1.3 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -22.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 1.24M USD
- Year-over-year change
- -2.1%
- 4-year CAGR
- -54.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | 1.24M | -2.1% |
| FY2024 | 2024-10-31 | 1.27M | +38.9% |
| FY2023 | 2023-10-31 | 915K | -92.6% |
| FY2022 | 2022-10-31 | 12.36M | -57.6% |
| FY2021 | 2021-10-31 | 29.13M | — |
Cash & Equivalents vs competitors
How ANIX compares with its peers on the latest reported figures
- ANIX's Apr 2026 cash & equivalents of $1.48M is the lowest of the 10 companies compared; the peer median is $35M.
- Its year-over-year change of -22.7% is the 8th highest of 10, against a peer median of +14.8%.
- Cash & equivalents amounts to 9.9% of total assets for ANIX, versus a peer median of 38.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
IRDOpus Genetics, Inc. | Mar 2026 | $59.96M | +43.5% | +1.9% | 89.8% |
| Mar 2026 | $56.13M | +14.8% | -28.3% | 95.1% | |
| Mar 2026 | $51.8M | +71.7% | -25.4% | 38.8% | |
| Mar 2026 | $47.32M | -9.8% | -3.9% | 17.4% | |
| Mar 2026 | $35M | +89.3% | -74.4% | 18.8% | |
| Mar 2026 | $26.27M | -34.2% | -1.5% | 52.8% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $8.13M | +109.1% | -13.7% | 91.3% |
| Mar 2026 | $6.3M | +1.3% | -36.7% | 21.2% | |
| Mar 2026 | $4.14M | -67.1% | -16.7% | 31.5% | |
| Apr 2026 | $1.48M | -22.7% | -53.5% | 9.9% | |
| Peer median (excluding ANIX) | $35M | +14.8% | -16.7% | 38.8% | |
Competitors are the stored peer set for ANIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 29.13M | 12.36M | 915K | 1.27M | 1.24M |
| Short-term Investments | 6.6M | 17.33M | 22.93M | 18.65M | 13.93M |
| Net Receivables | 0 | 46K | 270K | 173K | 0 |
| Inventory | 0 | (46K) | 0 | 0 | 0 |
| Other Current Assets | (444) | 46K | 1.24M | 1.27M | 713K |
| Total Current Assets | 36M | 30.2M | 25.36M | 21.36M | 15.89M |
| Property, Plant & Equipment (Net) | 253.96K | 212K | 166K | 229K | 193K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 253.96K | 212K | 166K | 229K | 193K |
| Total Assets | 36.26M | 30.41M | 25.52M | 21.59M | 16.08M |
| Account Payables | 136K | 265K | 206K | 525K | 165K |
| Short-term Debt | 0 | 0 | 0 | 0 | 41K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 922K |
| Total Current Liabilities | 1.27M | 2.04M | 2.03M | 2.5M | 1.97M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 82 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 220.08K | 175K | 123K | 203K | 163K |
| Total Liabilities | 1.49M | 2.21M | 2.15M | 2.7M | 2.13M |
| Common Stock | 300.51K | 309K | 311K | 322K | 330K |
| Retained Earnings | (204.79M) | (218.39M) | (228.2M) | (240.75M) | (251.68M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | (670.51K) | (847K) | (966K) | (1.11M) | (1.21M) |
| Total Equity | 34.77M | 28.2M | 23.37M | 18.89M | 13.95M |
| Total Debt | 259K | 221K | 175K | 232K | 204K |
| Net Debt | (28.83M) | (12.14M) | (740K) | (1.04M) | (1.04M) |
Anixa Biosciences, Inc.
NASDAQ:ANIX
Intrinsic Alpha fair value
Locked
Current Price
$2.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.